Dr. Luis Hernando Camacho, MD, MPH

Dr. Camacho practices at Medical Center Endoscopy in Houston, Texas.

Dr. Camacho's NPI, 1336249960, was assigned on September 24, 2006. Dr. Camacho graduated from Military University Nueva Granada in 1988. Dr. Camacho holds Texas license L2829.

Dr. Camacho's primary practice is Medical Center Endoscopy, at 6560 Fannin Suite 600, Houston, TX 77030. The practice phone is (713) 790-1512.

Dr. Camacho's primary practice is Medical Center Endoscopy in Houston, Texas. Dr. Camacho is also affiliated with Houston Methodist Hospital. Dmand AI also links Dr. Camacho to 4 more hospitals and 1 physician office, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Camacho practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Camacho's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Camacho is board certified in medical oncology by the American Board of Internal Medicine. Dr. Camacho is licensed in Texas.

Dmand AI lists breast cancer, chronic anemia, chronic embolism thrombosis, chronic leukemia, deep vein thrombosis (DVT), lung cancer, lymphoma and multiple myeloma among the conditions Dr. Camacho treats.

CMS data shows 13,260 Medicare services from Dr. Camacho across 16 procedure codes in 2024, for 176 Medicare patients. Medicare paid $77,634 for them.

CMS counts 176 Medicare patients who saw Dr. Camacho in 2024. The largest group is 65 to 74, with 80 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 7% are also on Medicaid. Their average risk score is 2.32, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Camacho's median patient age at 56, with 59% women.

In 2024, Dr. Camacho wrote 667 Medicare Part D claims for 83 patients. 58% of them were for generic drugs. CMS names the drug for 434 of them, across 19 drugs with 11 or more claims each, at $1,635,044 in total drug cost. In 2023, CMS named 440 claims across 22 drugs.

Dr. Camacho accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Camacho as offering telehealth.

Dmand AI links 70 papers to Dr. Camacho, published from 2006 to 2024. 2014 was the busiest year, with 5. The most frequent topics are Antineoplastic Agents, Melanoma and Antineoplastic Combined Chemotherapy Protocols. Dr. Camacho has published most often in Cancer. Dr. Camacho's most frequent co-authors are Agop Y. Bedikian, MD, Chaan S. Ng and Jeffrey E. Gershenwald, MD.

Dmand AI links Dr. Camacho to 3 clinical trials, 2 of them phase 1 studies. 1 is still active or recruiting. Conditions studied include Melanoma and Nevi and Melanomas. Jiangsu HengRui Medicine Co., Ltd. sponsors the most, 2.

CMS Open Payments shows 1,354 general payments to Dr. Camacho from 62 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 73% of the total. Merck Sharp & Dohme Corporation paid the most, $408,462.

Dr. Camacho graduated from Military University Nueva Granada in 1988. Dr. Camacho is a member of ACP and ASCO.

Dr. Camacho is in network with 11 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 7. Check the plan with the practice before a visit.